Nanotechnology in Ankylosing Spondylitis: Advancements in Drug Delivery and Targeted Therapy

Ankylosing spondylitis is a chronic inflammatory disorder primarily affecting the spine and the sacroiliac joints, although it is now considered for new drug target possibilities. It is an area in which nanotechnology has shown significant potential. This report offers an extensive review of the formulation design, clinical utility, and current development in the use of nanotechnology for treating AS. The rational design principles of nanotherapeutics, created to modify the myriad processes implicated in AS pathophysiology, were examined. It comprises drug delivery systems, targeting approaches, and release processes. Clinical and preclinical evidence of nanomedicines’ tolerability and effectiveness in AS therapy is reported. In conclusion, this document reflects the recent state of these nanotechnology-based treatments for AS and discusses the author’s future goals in developing novel, powerful treatment strategies that generate strong patient outcomes.